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Despite optimized therapeutic approaches, coronary heart
disease with its secondary diseases, such as myocardial in-
farction and chronic heart failure, as well as embolic stroke
are the main causes of morbidity and mortality. They re-
sult from inflammatory processes induced by lipoproteins
such as oxidized low-density lipoprotein (LDL), VLDL and
lipoprotein(a) (Lp(a)).
Fifty years after the first publication by Kare Berg from
Oslo, Lp(a) has meanwhile been accepted as an individual
risk factor. However, in spite of the increasing scientific
interest in Lp(a), biological function and biosynthetic and
catabolic processes of this molecule are still widely un-
known. Furthermore, the exact laboratory determination of
Lp(a) plasma concentration and its different isoforms is still
challenging.
The individual Lp(a) serum concentration is genetically
determined and remains relatively constant thoughout life.
Some ethnic groups in Arabic and African countries show
very high Lp(a) plasma concentrations.
In the meantime, several registries have indicated that
a high Lp(a) plasma concentration is associated with an
increased incidence of coronary heart disease, aortic valve
This Editorial is part of the special issue “Lp(a) – the
underestimated cardiovascular risk factor”.
 Klaus-Peter Mellwig
kpmellwig@hdz-nrw.de
1 Klinik für Kardiologie, Herz- und Diabeteszentrum NRW,
Ruhr-Universität Bochum, Georgstr. 11, 32545 Bad
Oeynhausen, Germany
stenosis and heart failure. However, there is still no sys-
tematic analysis of the population in order to assess their
cardiovascular risk depending on Lp(a).
For the first time, the European Society of Cardiology
has now included Lp(a) determination in the extended
screening for the assessment of the cardiovascular risk.
In Germany, there are still no effective drugs to lower
Lp(a) plasma concentration. Neither are the recently ap-
proved PCSK9 inhibitors expected to significantly improve
therapeutic options. Thus, lipid apheresis has to be regarded
as the only effective therapeutic option to decrease cardiac
events.
Against this background, the contributions to the present
supplement are intended to focus on the clinical aspects of
Lp(a) and to emphasize the importance of lipid apheresis.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
K
